Because impaired lipid metabolism leads to obesity and related metabolic diseases, such as dyslipidemia, atherosclerosis, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) [10,11,12], improved PPARα activity is required to prevent or treat this group of disorders. This evidence concerns the gene PPARA and obesity disorder.